The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
Open accessAbstract
Next-generation sequencing technologies have greatly expanded our understanding of cancer genetics. Antisense technology is an attractive platform with the potential to translate these advances into improved cancer therapeutics, because antisense oligonucleotide (ASO) inhibitors can be designed on the basis of gene sequence information alone. Recent human clinical data have demonstrated the potent activity of systemically administered ASOs targeted to genes expressed in the liver. We describe the preclinical activity and initial clinical evaluation of a class of ASOs containing constrained ethyl modifications for targeting the gene encoding the transcription factor STAT3, a notoriously difficult protein to inhibit therapeutically. Systemic delivery of the unformulated ASO, AZD9150, decreased STAT3 expression in a broad range of preclinical cancer models and showed antitumor activity in lymphoma and lung cancer models. AZD9150 preclinical activity translated into single-agent antitumor activity in patients with highly treatment-refractory lymphoma and non-small cell lung cancer in a phase 1 dose-escalation study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The naked, antisense, modified oligonucleotide, AZD9150 (danvatirsen), targets STAT3 and demonstrated antitumor activity in a Phase 1 dose-escalation study in patients with highly treatment-refractory lymphoma and NSCLC”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560
Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. E., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 724
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Cited by
Sorted by citations
Items 401–449 of 449
RNA‐Binding Proteins: Function, Biological Mechanisms, and Therapeutic Opportunities
Li, L., Yan, X., Ji, Q., & Zhang, H. (2026) · MedComm · doi:10.1002/mco2.70938 · Cited by 1
An All-Nanocrystal Biosensing System for In Vitro Detection of STAT3 Oligonucleotides
Kong, W., Lam, C. W., & Wang, F. (2017) · Molecules · doi:10.3390/molecules22071085 · Cited by 1
Antisense Oligonucleotides: Concepts and Pharmaceutical Applications
Araya, A. K., Arias, D., Coto, K., López, M. R., Rivera, J., & Mora, J. J. (2023) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v6i1.2092 · Cited by 1
Rodrigues, A. M., Fiore, A. P. Z. P., Guardia, G. D. A., Tomasin, R., Teixeira, A. A. R., Giordano, R. J., Schechtman, D., Pagano, M., Galante, P. A. F., & Bruni‐Cardoso, A. (2024) · Oncogene · doi:10.1038/s41388-024-03104-2 · Cited by 1
STAT3 as a Major Contributor to Chemoresistance
Lee, D. S., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00007-x · Cited by 1
Yang, Z., Xu, H., Yang, Y., Duan, C., Zhang, P., Zhou, Y., Wang, X., Pan, L., Wang, Y., Fu, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1238979/v1 · Cited by 1
Strategies for Targeting the JAK ‐ STAT Pathway in Lymphoid Malignancies
Feith, D. J., Ung, J., Elghawy, O., Yue, P., Turkson, J., & Loughran, A. T. P. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch27 · Cited by 1
Madabushi, S. S., Brooks, J., Zuro, D. M., Su, Y., Kaniowski, D., Ghimire, H., Lim, J. E., Abdelhamid, A. M. H., Kuo, Y., Marcucci, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.14.653587 · Cited by 1
Detection of viral induced double-stranded RNA intermediates in archival paraffin blocks
Hostetter, G. H., Collins, E., Berghius, B., Turner, L., Hudson, E., Sempere, L. F., & Jewell, S. D. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.041
A sensible approach to targeting STAT3-mediated transcription
Bhola, N. E., Johnson, D. E., & Grandis, J. R. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.10.51
Halsne, R. (2016) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.15.1370
Clay, T. D. (2017) · Minerva Access (University of Melbourne)
Bartkowiak, T. (2017) · Digital Commons-TMC (Texas Medical Center)
The Role of STAT3 in the Pathogenesis of Chronic Lymphocytic Leukaemia
Brophy, S. (2018) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Antisense Technology: Liver Targeting and Beyond for Drug Discovery
Geary, R. S., Baker, B. F., & Monia, B. P. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00062
Self-citationCurrent Advances in Immuno-oncology for Head and Neck Cancer
Devlin, M.-J., & Forster, M. D. (2017) · International Journal of Head and Neck Surgery · doi:10.5005/jp-journals-10001-1340
Paidikondala, M., Rangasami, V. K., Nawale, G. N., Casalini, T., Perale, G., Kadekar, S., Mohanty, G., Salminen, T., Oommen, O. P., & Varghese, O. P. (2019) · Angewandte Chemie · doi:10.1002/ange.201900099
Nicolas, A. M. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68107
Yang, Z., Xu, H., Yang, Y., Duan, C., Zhang, P., Wang, Y., Fu, K., Shen, Y., & Xu, M. X. (2022) · Research Square · doi:10.21203/rs.3.rs-1238979/v2
Cancer Stem Cells as the Key to Cancer: Special Emphasis on Prostate Cancer
Kassm, G. A., Antar, G., Atwi, M., Butrus, T., Hajjar, E., Jaafar, O., Machrekeki, M., Mikhael, E., Swesa, J., Mikhae, F., et al. (2023) · Global Journal of Medical Research · doi:10.34257/gjmrfvol23is2pg17
Alternative Splicing and Cancer
Choksi, A., Pant, R., Nakka, K. K., Singh, M., Upreti, A., & Chattopadhyay, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_3
Design, Synthesis, and Biological Evaluation of Benzo[B]Thiophene 1,1-Dioxide (BTP) DerivativesPreprint
Ding, L., Li, X., Yan, W., Liu, X., Deng, F., Chen, X., Zhang, Y., Jia, Q., & He, D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4565703
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Salter, A. I., & Das, M. S. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-735
Targeting Stat3 Potentiates Cdk4/6 Inhibitors Therapy in HnsccPreprint
Lin, D., Sun, H., Liu, C., Wang, M., Sun, M., Zheng, J., Yu, X., Shi, R., Wang, B., Zhou, Q., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4779054
Recent advances in the medicinal chemistry of antisense oligonucleotides
Ito, K. R., Uda, K., & Obika, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00031-5
Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3
Vasilescu, A.-G., Vasilescu, A.-M., Sima, L. E., Baran, N., & Szedlacsek, S. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1673427
Developing antisense therapeutics for multiple myeloma
Kapphahn, A., Truong, N., Khan, M., Ashitey, A., Alfano, D., & Gupta, A. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102923
Monteiro, S. A., de Carvalho, L. A. V., & da Silva, F. A. B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.05.686831
Liu, J., & Gao, Y. (2025) · Chemical Communications · doi:10.1039/d5cc05511c
Leboff, C., Mendoza, P. D. C., Hatziapostolou, M., & Polytarchou, C. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70634
The role of IL-6 in tumor immunity and related research progress
Huang, P., Yin, R., Xu, W., Wang, S., Yong, H., & Yang, T. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112460
Bouaouiche, S. (2018) · theses.fr (ABES) · doi:10.70675/85185e48z640cz4823z8ea3z8f24dc88fcdd
Le développement préclinique des tcDNA pour la Dystrophie Musculaire de Duchenne
Aupy, P. (2019) · theses.fr (ABES) · doi:10.70675/308d569bzf97az413bz805fzc8aaca0427df
Mécanisme de régulation de l’activité du microARN miR-16 dans le mélanome uvéal
Quéméner, A. M. (2020) · theses.fr (ABES) · doi:10.70675/b6a2cadfz77d7z48b6zb573zaab26d81396e
RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions
Bouillon, M., Lapoujade, C., Basset, L., Fontaine, A., Hollenstein, M., Garcion, E., & Rousseau, A. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201213
The role of noncoding RNAs in host–Cryptosporidium interactions
Deng, S., Liu, J., Sun, M., Chen, X., & Li, J. (2026) · Trends in Parasitology · doi:10.1016/j.pt.2026.04.006
El-Kady, H. A., Hatem, S. H., Mandour, H. W., Abdelgilil, M. E., Hesham, M. A., Badr, D. M., Farrag, F. A., Abdallah, S. K., Sayed, A. O., Abdelzaher, S. M., et al. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00635-w
Targeting conventionally intractable cancer-driving proteins: What has been achieved recently?
Xie, Q., Xu, W., Wang, Y., & Ma, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119102
Therapeutic potential of antisense oligonucleotides in hematological malignancies
Cousin, É., Picard, A., Perrudin, E., Oundjian, M., Tardif, N., Quéméner, A. M., Rio, A.-G., Galibert, M., Gandemer, V., & Mazurier, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119808
STAT3 signaling inhibitors for cancer treatment
Akinsola, R., Xian, J., & Turkson, J. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.07.004
Jabeen, A., Javeed, T., Jan, N., Sofi, S., Masoodi, G., Ahanger, S. A., & Mir, M. A. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04540-0
Zheng, T., Li, H., Yao, L., Zhang, Y., Feng, L., & Yang, D. (2026) · Cells · doi:10.3390/cells15171624
Feng, X., Li, N., Chen, X., Cao, X., Dai, J., Xiong, S., & Yuan, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118532
Metadata
- Authors
- Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., Lee, S. J., Yamashita, M., Hughes, S. G., Fayad, L., Piha-Paul, S., Nadella, M. V. P., Mohseni, M., Lawson, D., Reimer, C., Blakey, D. C., Xiao, X., Hsu, J., Revenko, A., Monia, B. P., & MacLeod, A. R.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Moores Cancer Center (US)
- Ionis Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Mary Crowley Cancer Research Center (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Hong, David
- Kurzrock, Razelle
- Kim, Youngsoo
- MacLeod, A. Robert
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-11-18
- Volume
- 7
- Issue
- 314
- Pages
- 314ra185-314ra185
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5279222
- OpenAlex
- W2174791834
- Cited by
- 445
- References
- 60
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 41 · 2021: 48 · 2020: 46 · 2019: 52 · 2018: 50 · 2017: 33 · 2016: 30 · 2015: 1
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Isis Pharmaceuticals Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- antisense oligonucleotides, STAT3 inhibition, lymphoma, non-small cell lung cancer, anticancer activity, treatment-refractory cancer, systemic drug delivery, transcription factor inhibition
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Lymphoma, Male, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Oligonucleotides, Time Factors, Down-Regulation, Gene Expression Regulation, Neoplastic, Oligonucleotides, Antisense, Mice, SCID, Mice, Inbred NOD, Treatment Outcome, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Cell Proliferation, STAT3 Transcription Factor, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
